Compare NWN & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NWN | ADPT |
|---|---|---|
| Founded | 1859 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.5B |
| IPO Year | 2018 | 2019 |
| Metric | NWN | ADPT |
|---|---|---|
| Price | $52.78 | $16.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $49.50 | $17.78 |
| AVG Volume (30 Days) | 242.2K | ★ 1.6M |
| Earning Date | 06-01-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.75% | N/A |
| EPS Growth | 36.45 | ★ 63.89 |
| EPS | ★ 2.77 | N/A |
| Revenue | ★ $1,289,363,000.00 | $276,976,000.00 |
| Revenue This Year | $8.97 | $3.98 |
| Revenue Next Year | $4.27 | $22.72 |
| P/E Ratio | $18.97 | ★ N/A |
| Revenue Growth | 11.83 | ★ 54.77 |
| 52 Week Low | $38.94 | $6.26 |
| 52 Week High | $53.66 | $20.76 |
| Indicator | NWN | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 71.77 | 50.88 |
| Support Level | $45.72 | $14.87 |
| Resistance Level | N/A | $17.72 |
| Average True Range (ATR) | 1.24 | 0.76 |
| MACD | 0.29 | 0.09 |
| Stochastic Oscillator | 82.59 | 79.33 |
Northwest Natural Holding Co is a public natural gas service supplier operating in the U.S. Pacific Northwest. Its subsidiary, NW Natural, operates through the natural gas distribution segment, which purchases and distributes natural gas through which operates in Oregon and southwest Washington. The company operates in one reportable business segment, which is NW Natural's local gas distribution business and is referred to as the NGD segment. The company generates its revenue from residential, commercial, and industrial customers, the majority of which are in Oregon. Residential and commercial customers account for the vast majority of profitability.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).